RRG001

DRUG2 trials

Sponsors

Shanghai Refreshgene Technology Co., Ltd., Li Xiaorong

Conditions

Neovascular Age-related Macular DegenerationPDR - Proliferative Diabetic Retinopathy

Early Phase 1

The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)

RecruitingNCT06412224

Li XiaorongPDR - Proliferative Diabetic Retinopathy

Start: 2023-12-20End: 2028-12-31Target: 6Updated: 2024-05-14

Phase 1

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

RecruitingNCT06141460

Shanghai Refreshgene Technology Co., Ltd.Neovascular Age-related Macular Degeneration

Start: 2023-12-12End: 2030-12-31Target: 48Updated: 2024-11-14